TY - JOUR
T1 - Choline availability and acetylcholine synthesis in the hippocampus of acetylcholinesterase-deficient mice
AU - Hartmann, Joachim
AU - Kiewert, Cornelia
AU - Duysen, Ellen G.
AU - Lockridge, Oksana
AU - Klein, Jochen
N1 - Funding Information:
This study was supported by US Army Medical Research and Materiel Command DAMD17-01-2-0036 (to O.L.) and National Institute on Aging grant 1RO3AG25045 (to J.K.). We also thank the Alzheimer's Association for financial support (IIRG-04-1178 to J.K.) and Dr. Konrad Löffelholz (University of Mainz, Germany) for helpful discussions.
PY - 2008/5
Y1 - 2008/5
N2 - Mice deficient for acetylcholinesterase (AChE) have strongly increased extracellular levels of acetylcholine (ACh) in the dorsal hippocampus [Hartmann, J., Kiewert, C., Duysen, E.G., Lockridge, O., Greig, N.H., Klein, J., 2007. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J. Neurochem. 100, 1421-1429]. Using microdialysis, we found that increased ACh levels are accompanied by decreased levels of extracellular choline which were 1.60 μM in AChE-deficient mice and 4.36 μM in wild-type mice. Addition of choline (10 μM) to the perfusion fluid, while ineffective in wild-type animals, more than doubled extracellular ACh levels in AChE-deficient mice. High-affinity choline uptake (HACU), as measured ex vivo in corticohippocampal synaptosomes, was more than doubled in AChE-deficient mice. Inhibition of HACU by hemicholinium-3 (HC-3) in vivo reduced extracellular levels of ACh by 60% in wild-type mice but by more than 90% in AChE-deficient mice. Decreased ACh levels caused by infusion of HC-3 or tetrodotoxin (TTX) were accompanied by increased levels of free choline. Infusion of scopolamine (1 μM) caused a fivefold increase of ACh levels in wild-type animals but only a 50% increase in AChE-deficient mice. In conclusion, absence of AChE causes dynamic changes in the ratio of choline to ACh. High levels of extracellular ACh are accompanied by reduced levels of extracellular choline, and ACh release becomes strongly dependent on choline availability. Similar changes may take place in patients chronically exposed to AChE inhibitors.
AB - Mice deficient for acetylcholinesterase (AChE) have strongly increased extracellular levels of acetylcholine (ACh) in the dorsal hippocampus [Hartmann, J., Kiewert, C., Duysen, E.G., Lockridge, O., Greig, N.H., Klein, J., 2007. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J. Neurochem. 100, 1421-1429]. Using microdialysis, we found that increased ACh levels are accompanied by decreased levels of extracellular choline which were 1.60 μM in AChE-deficient mice and 4.36 μM in wild-type mice. Addition of choline (10 μM) to the perfusion fluid, while ineffective in wild-type animals, more than doubled extracellular ACh levels in AChE-deficient mice. High-affinity choline uptake (HACU), as measured ex vivo in corticohippocampal synaptosomes, was more than doubled in AChE-deficient mice. Inhibition of HACU by hemicholinium-3 (HC-3) in vivo reduced extracellular levels of ACh by 60% in wild-type mice but by more than 90% in AChE-deficient mice. Decreased ACh levels caused by infusion of HC-3 or tetrodotoxin (TTX) were accompanied by increased levels of free choline. Infusion of scopolamine (1 μM) caused a fivefold increase of ACh levels in wild-type animals but only a 50% increase in AChE-deficient mice. In conclusion, absence of AChE causes dynamic changes in the ratio of choline to ACh. High levels of extracellular ACh are accompanied by reduced levels of extracellular choline, and ACh release becomes strongly dependent on choline availability. Similar changes may take place in patients chronically exposed to AChE inhibitors.
KW - Alzheimer's disease
KW - Hemicholinium-3
KW - High-affinity choline uptake
KW - Microdialysis
KW - Scopolamine
UR - http://www.scopus.com/inward/record.url?scp=40949154762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40949154762&partnerID=8YFLogxK
U2 - 10.1016/j.neuint.2007.10.008
DO - 10.1016/j.neuint.2007.10.008
M3 - Article
C2 - 18023504
AN - SCOPUS:40949154762
SN - 0197-0186
VL - 52
SP - 972
EP - 978
JO - Neurochemistry International
JF - Neurochemistry International
IS - 6
ER -